pSivida Corp

Investor Relations Home

pSivida develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. We have developed three of the four products approved in either the U.S. or the EU for sustained release delivery of drug to treat chronic back-of-the-eye diseases utilizing multiple generations of our Durasert technology system.

Our lead development product, ILUVIEN® is licensed to Alimera Sciences, Inc. and utilizes the third generation of the Durasert technology.The US Food and Drug Administration (FDA) approved ILUVIEN for the treatment of diabetic macular edema (DME) for patients treated with a course of corticosteroids and did not have a significant rise in intraocular pressure (IOP). ILUVIEN is marketed in the U.K., Germany and Portugal and has or is pending marketing autorization in 14 other EU countries.

pSivida’s other two FDA-approved products, Retisert® and Vitrasert®, licensed to Bausch & Lomb, Inc., are implants utilizing earlier generations of our Durasert technology system that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.

View all »   RSS

Recent Releases

Nov 5, 2015
pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results

Oct 30, 2015
pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information

IR Contacts

Beverly Jedynak
Martin E. Janis & Company
Phone: 312-943-1123

Transfer Agent:

Computershare Investor Services
P.O. Box 43078
Providence, RI 02940 USA
Phone: 781-575-2879
Fax: 781-575-3605